| Assessment Status | Rapid Review Complete |
| HTA ID | 24012 |
| Drug | Etrasimod |
| Brand | (Velsipity® |
| Indication | Etrasimod (Velsipity®) is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. |
| Assessment Process | |
| Rapid review commissioned | 11/05/2024 |
| Rapid review completed | 07/05/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that etrasimod not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. October 2024
